Tucson, AZ October 14, 2026 --(PR.com)-- ACQUICON 2026, taking place October 19–21, brings together business operators, family offices, private equity firms, venture investors, high-net-worth investors, investment bankers, and other capital providers focused on growth, investment, acquisitions, and strategic transactions.
MVT will provide an update on the Company’s progress and investment opportunity, including its portfolio of proprietary microbubble and nanobubble technologies designed to expand ultrasound from diagnostic imaging into therapeutic applications.
The presentation will highlight:
· CardiSon™, MVT’s next-generation ultrasound enhancing agent, which has completed Phase II clinical development and is advancing toward pivotal studies and a planned NDA submission.
· Solv™, MVT’s phase-shift nanobubble technology being developed under an FDA medical-device pathway for ultrasound-mediated treatment of microvascular obstruction following ST-elevation myocardial infarction.
· NanoBlate™, MVT’s focused-ultrasound therapeutic platform being developed under a medical-device pathway for noninvasive treatment of solid tumors, including brain and other difficult-to-treat cancers.
· MVT’s broader platform opportunities in targeted drug and gene delivery, blood-brain barrier applications, and ultrasound-mediated precision therapy.
“MVT has made substantial progress across each of our major development programs, and we look forward to updating investors at ACQUICON,” said Evan C. Unger, MD, Chief Executive Officer and Executive Chairman of Microvascular Therapeutics. “We believe our platform has the potential to transform ultrasound from primarily a diagnostic modality into a powerful therapeutic technology. ACQUICON provides an excellent opportunity to meet investors and strategic partners interested in participating in the next stage of MVT’s growth.”
MVT has also completed the Keiretsu Forum Northwest due diligence process and has a completed due diligence report available to qualified prospective investors. The report reviews the Company’s technologies, development programs, intellectual property, regulatory strategy, management team, and investment opportunity.
MVT is currently raising capital through a convertible note financing to support advancement of CardiSon toward pivotal development and regulatory submission, as well as continued development of Solv, NanoBlate, and the Company’s broader therapeutic ultrasound platform.
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology company developing proprietary microbubble and nanobubble technologies for diagnostic and therapeutic ultrasound. The Company’s founders previously developed Definity®, one of the world’s leading ultrasound enhancing agents. MVT’s pipeline includes CardiSon™, Solv™, NanoBlate™, and additional applications in targeted drug and gene delivery and ultrasound-mediated precision therapy.
Investor and Media Contact:
Evan C. Unger, MD
Chief Executive Officer and Executive Chairman
Microvascular Therapeutics, Inc.
e.unger@mvtpharma.com
Contact Information:
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
Contact via Email
mvtpharma.com
Read the full story here: https://www.pr.com/press-release/981562
Press Release Distributed by PR.com
